These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21619856)

  • 61. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drug safety and efficacy impaired by quality failure.
    Ekiert RJ
    Pharmazie; 2011 Jun; 66(6):467-9. PubMed ID: 21699091
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analytical characterisation of homoeopathic mother tinctures.
    Biber A; Franck-Karl G; Waimer F; Riegert U; Wiget R
    Pharmeur Sci Notes; 2009 Mar; 2009(1):1-4. PubMed ID: 19275866
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Study on chemical pattern recognition of Chinese herbal drugs and materia medica in past 10 years].
    Wu Z; Su W; Yuan S; Lin J; Wang P
    Zhong Yao Cai; 1999 Dec; 22(12):655-9. PubMed ID: 12918447
    [No Abstract]   [Full Text] [Related]  

  • 65. [Testing of medicinal products produced from pooled plasma].
    Unkelbach U; Hunfeld A; Breitner-Ruddock S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1181-4. PubMed ID: 25213735
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation.
    Mueller MM; Seifried E
    Transfus Clin Biol; 2006 Nov; 13(5):282-5; quiz 286-9. PubMed ID: 17196864
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fisheries and aquaculture industries involvement to control product health and quality safety to satisfy consumer-driven objectives on retail markets in Europe.
    Roth E; Rosenthal H
    Mar Pollut Bull; 2006; 53(10-12):599-605. PubMed ID: 17070860
    [TBL] [Abstract][Full Text] [Related]  

  • 68. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS; Cichutek K
    Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Viral safety of biological products in WHO policy.
    Grachev VP
    Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The regulation of medicinal products derived from human blood or plasma in the European Community.
    Brunko P
    Dev Biol Stand; 1993; 81():269-71. PubMed ID: 8174813
    [No Abstract]   [Full Text] [Related]  

  • 71. Development of a cell-based medicinal product: regulatory structures in the European Union.
    Gálvez P; Clares B; Hmadcha A; Ruiz A; Soria B
    Br Med Bull; 2013; 105():85-105. PubMed ID: 23184855
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of feed additives and contaminants: an essential component of food safety.
    Mantovani A; Maranghi F; Purificato I; Macrì A
    Ann Ist Super Sanita; 2006; 42(4):427-32. PubMed ID: 17361066
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The hygienic examination and quality research of Chinese crude drug scorpion].
    Zhang G; Lü X; An X; Lian L; Kawamura T
    Zhong Yao Cai; 2001 Nov; 24(11):788-91. PubMed ID: 15575160
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
    Montag-Lessing T; Störmer M; Schurig U; Brachert J; Bubenzer M; Sicker U; Beshir R; Spreitzer I; Löschner B; Bache C; Becker B; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):45-51. PubMed ID: 20012926
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of the chemical compatibility of plastic contact materials and pharmaceutical products; safety considerations related to extractables and leachables.
    Jenke D
    J Pharm Sci; 2007 Oct; 96(10):2566-81. PubMed ID: 17701994
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A risk assessment on extraneous virus contamination in a viral vaccine production environment justifies waiving of in vivo testing.
    Westergaard UB; van Overeem Hansen B; Rud KA; Nielsen C; Stawski G; Hasløv KR
    Biologicals; 2018 Nov; 56():9-12. PubMed ID: 30173936
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety assurance for biologics manufactured in mammalian cell cultures: a multitiered strategy.
    Chen D
    Adv Biochem Eng Biotechnol; 2014; 139():167-83. PubMed ID: 23719711
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
    Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Absorption spectra of electronic-homoeopathic copies of homoeopathic nosodes and placebo have essential differences.
    Korenbaum VI; Chernysheva TN; Apukhtina TP; Sovetnikova LN
    Forsch Komplementmed; 2006 Oct; 13(5):294-7. PubMed ID: 17057390
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Important aspects of virus safety of advanced therapy medicinal products].
    Blümel J; Stühler A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):38-44. PubMed ID: 19937308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.